ScreenerHero

SNOASonoma Pharmaceuticals, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · sonomapharma.com
1.340USD-1.47%Mkt Cap: 6.42M $P/E: —

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United State…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap6.42M $
Enterprise Value1.82M $
Revenue (TTM)21.92M $
Gross Profit7.42M $
Net Income (TTM)-3.17M $
Revenue/Share9.807 USD
Last Price1.340 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.39
PEG1.08
EV/EBITDA-1.43
EV/Revenue0.08
P/S0.29
P/B0.78
EPS (TTM)-1.20
EPS (Forward)-0.56
52W Range
0.850010% of range5.600
52W High5.600 USD
52W Low0.8500 USD
Profitability
Gross Margin37.97%
Oper. Margin-0.62%
EBITDA Margin-5.80%
Profit Margin-16.26%
ROE-102.58%
ROA-22.74%
Growth
Revenue Growth59.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.93M $
CapEx (TTM)192.00K $
FCF Margin-6.71%
FCF Yield-22.91%
Net Debt-4.60M $
Net Debt/EBITDA3.62
Balance Sheet
Debt/Equity0.27
Current Ratio2.99
Quick Ratio1.56
Book Value/Sh1.720 USD
Cash/Share1.115 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 20, 2019
Splits
Last Split1:20
Split DateAug 30, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.79M
Float4.77M
Insiders0.42%
Institutions2.31%
Short Interest
Short Ratio0.1d
Short % Float0.18%
Short % Out.0.18%
Shares Short8.45K
Short (prev mo.)82.83K
Technical
SMA 501.207 (+11.0%)
SMA 2002.278 (-41.2%)
Beta1.29
S&P 52W Chg18.16%
Avg Vol (30d)168.87K
Avg Vol (10d)266.94K
Technical Indicators
RSI (14)57.0
MACD0.0441
MACD Signal0.0322
MACD Hist.+0.0119
BB Upper1.460 USD
BB Middle1.238 USD
BB Lower1.015 USD
BB Width35.92%
ATR (14)0.0908 USD
Vol Ratio (20d)0.30x